Abstract
Introduction: Four randomised trials have shown that dose escalated prostate radiotherapy (DEPRT) improves tumour related outcomes, using additional fractions (3 photons, 1 proton) to deliver the boost (additional dose 11–15.6%). Two of the three trials performing a subgroup analysis did not show an advantage in their low-risk group patients. The aim of this study was to estimate the additional number of fractions required to implement DEPRT locally.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Clinical oncology (Royal College of Radiologists (Great Britain))
Paper Title
Journal
Date
